Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Allianthera Boston Inc. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to examiner SCHMIDT, IZABELA MARIA, who is the busiest examiner for the portfolio with 1 pending matter. The data indicates 1 distinct examiner and 1 distinct art unit are involved in the current prosecution. For a practitioner, this narrow focus means that the success of the company's active patenting efforts depends on a single examiner's review. No other examiners or units are currently providing feedback on the company's applications.
With 1 pending office action, the company's active presence at the patent office is quite small. The concentration in 1 distinct art unit allows the practitioner to focus on the specific guidelines of that unit. SCHMIDT, IZABELA MARIA is the only examiner currently reviewing the company's pending work, making their individual examination style the primary factor in the prosecution. The Biotechnology & Pharmaceuticals technology area suggests the pending matter involves complex biological or pharmaceutical subject matter. The 1 distinct examiner and 1 distinct art unit structure creates a very streamlined administrative process for this company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18706816 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18706816 | NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF | SCHMIDT, IZABELA MARIA | 1621 | §102 | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllianthera Boston Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Izabela Maria Schmidt has the most, with 1 of Allianthera Boston Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
